China Universal Asset Management Company’s Structure Therapeutics GPCR Stock Holding History

China Universal Asset Management Company’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$666K	Sell	12,409 -1,415	-10%	-$62.6K	0.04%	242
2026 Q1	$666K	Buy	13,824 +2,936	+27%	+$201K	0.05%	239
2025 Q4	$757K	Buy	10,888 +444	+4%	+$18.1K	0.06%	210
2025 Q3	$292K	Sell	10,444 -1,523	-13%	-$30.3K	0.02%	297
2025 Q2	$248K	Buy	11,967 +16	+0.1%	+$352	0.02%	293
2025 Q1	$207K	Sell	11,951 -683	-5%	-$16.7K	0.02%	311
2024 Q4	$343K	Buy	12,634 +1,174	+10%	+$41.7K	0.03%	284
2024 Q3	$503K	Buy	11,460 +5,707	+99%	+$221K	0.06%	217
2024 Q2	$226K	Sell	5,753 -3,623	-39%	-$149K	0.03%	224
2024 Q1	$402K	Buy	9,376 +5,027	+116%	+$212K	0.05%	204
2023 Q4	$177K	Buy	4,349 +2,939	+208%	+$168K	0.03%	216
2023 Q3	$71.1K	Sell	1,410 -25,857	-95%	-$833K	0.02%	218
2023 Q2	$1.13M	Buy	+27,267	New	+$764K	0.35%	73

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

China Universal Asset Management Company's GPCR Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Structure Therapeutics (GPCR) stake by 10% in Q2 2026, selling an estimated $62.6K and leaving 12,409 shares worth $666K. The position accounts for 0.04% of the portfolio, ranked #242.

China Universal Asset Management Company first reported a position in GPCR in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.13M in Q2 2023. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

China Universal Asset Management Company held 12,409 shares of Structure Therapeutics worth $666K as of Q2 2026.
China Universal Asset Management Company sold 1,415 Structure Therapeutics shares in Q2 2026, an estimated $62.6K.
Structure Therapeutics made up 0.04% of China Universal Asset Management Company's portfolio in Q2 2026, its #242 holding.
China Universal Asset Management Company first reported a position in Structure Therapeutics in Q2 2023 and has held it in 13 quarters since.
China Universal Asset Management Company's Structure Therapeutics position peaked at $1.13M in Q2 2023.
191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.